Expression and Clinical Significance of Heparanasein Osteosarcoma.
10.4055/jkoa.2006.41.1.43
- Author:
Han Soo KIM
1
;
June Hyuk KIM
;
Joo Han OH
;
Mi Ra LEE
;
So Mi SEOL
;
Sang Hoon LEE
Author Information
1. Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul, Korea. ohjh1@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Osteosarcoma;
Heparanase;
Immunohistochemistry;
Local recurrence;
Metastasis;
Prognosis
- MeSH:
Biomarkers;
Humans;
Immunohistochemistry;
Multivariate Analysis;
Neoplasm Metastasis;
Osteosarcoma*;
Prognosis;
Recurrence;
Risk Factors;
Survival Rate
- From:The Journal of the Korean Orthopaedic Association
2006;41(1):43-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study examined the expression of heparanase in osteosarcomas and evaluated its prognostic value. MATERIALS AND METHODS: The immunohistochemical expression of heparanase from 51 osteosarcoma tissues was examined, and the correlations between the heparanase expression level and the clinicopathological factors were evaluated. RESULTS: Heparanase over-expression was observed in 37 tissue samples. There was a correlation between the heparanase expression level and a poor chemotherapeutic response, metastasis and poor survival rate. Multivariate analyses revealed that heparanase over-expression was a significant independent risk factor for a distant metastasis of an osteosarcoma. Among the 46 patients who underwent an adequate wide resection, there was a correlation between the heparanase expression level and recurrence. The 5-year survival rate was 83.8% for patients with heparanase negative tumors, and 46.9% for those with heparanase over-expression. Multivariate analysis using the Cox regression model revealed the heparanase expression level to be an independent prognostic indicator. CONCLUSION: These results indicate that heparanase expression might play an important role in local recurrence and metastasis, and might be a biological marker of the prognostic significance in osteosarcoma patients.
